

**For immediate release**

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.**

**Results of Extraordinary General Meeting and Subdivision of Share Capital**

Integrated Diagnostics Holdings ("**IDH**" or the "**Company**"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, announces that, further to its circular posted on 4 December 2020 (the "**Circular**"), at the Extraordinary General Meeting (the "**EGM**") of the Company held earlier today at the headquarters of IDH Integrated Diagnostics Holdings, Building B216-F7, Smart Village, Giza, Egypt, all resolutions contained in the notice of the meeting appended to the Circular were duly passed.

Further information on the resolutions and the voting report will be available on the Company's website at <https://investors.idhcorp.com/>

Under Listing Rule 9.6, a copy of the resolutions will be submitted to the National Storage Mechanism, and available to view at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The Company will now progress the Subdivision (as defined in the Circular).

Subdivision

Following the passing of the relevant resolutions at the EGM, with effect from tomorrow, the Company's existing issued ordinary share capital of 150,000,000 ordinary shares of US\$1.00 each (the "**Existing Ordinary Shares**") will be sub-divided on the basis of one Existing Ordinary Shares into four new ordinary shares of US\$0.25 each (the "**New Ordinary Shares**"). Details of the Subdivision and the effect on

shareholders were set out in the Circular.

The ISIN of the New Ordinary Shares is JE00BLKGSR75 and the SEDOL is BLKGSR7. The New Ordinary Shares are expected to be admitted to trading on the Main Market of the London Stock Exchange at 8.00 am (or as soon as practicable thereafter) on 24 December 2020.

The proportion of the Company's issued ordinary share capital held by each shareholder immediately before and after the Subdivision will remain unchanged.

Shareholders who held their Existing Ordinary Shares in CREST prior to the Subdivision will have the New Ordinary Shares credited to their CREST accounts as soon as practicable today. Shareholders who held their Existing Ordinary Shares in certificated form will have new share certificates evidencing the New Ordinary Shares to which they are entitled dispatched to them by first-class post by on or around 4 January 2021.

### Total Voting Rights

With effect from tomorrow, the Company's issued ordinary share capital will comprise 600,000,000 New Ordinary Shares, with one voting right each. The Company does not hold any shares in treasury. This figure of 600,000,000 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

### **About Integrated Diagnostics Holdings (IDH)**

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 471 branches as of 30 September 2020, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015. Learn more at [idhcorp.com](http://idhcorp.com).

## Contact

**Nancy Fahmy**

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |

[nancy.fahmy@idhcorp.com](mailto:nancy.fahmy@idhcorp.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMFZMZZFFDGGZM